Observational studyRevista peruana de medicina experimental y salud publica2026
Candida species identified by MAL-DI-TOF and antifungal susceptibility in hospitalized patients with COVID-19 in Peru.
Observational study in Revista peruana de medicina experimental y salud publica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To identify Candida species using MALDI-TOF and analyze their antifungal susceptibility from Candida genus isolates in hospitalized patients with COVID-19 between November 2020 and April 2022. Materials and methods: An observational, descriptive, and cross-sectional study based on the se-condary analysis of microbiological and clinical-epidemiological data from 260 Candida isolates, primarily from urine, respiratory secretions, and blood cultures, referred to the National Reference Laboratory of Mycology of the National Institute of Health. Identification was performed using phenotypic techniques and MALDI-TOF, and antifungal susceptibility was evaluated using disk diffusion and broth microdilution according to Clinical and Laboratory Standards Institute (CLSI) criteria. Results: Candida albicans was the most prevalent species (64.6%), followed by Candida tropicalis, Candida glabrata, Candida parapsilosis, and Candida auris. Most isolates showed susceptibility to voriconazole and caspofungin, while varying percentages of susceptibility to fluconazole were observed, especially in C. glabrata and C. auris. Minimum inhibitory concentration (MIC) values showed variability between species and antifungals. Conclusions: Non-albicans species represented a considerable proportion of the analyzed isolates. These findings descri-be the pattern of species and antifungal susceptibility in strains referred to the National Reference Labora-tory of Mycology of the National Institute of Health during the COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.